Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases
Approved by the Tianjin Municipal Science and Technology Commission and the Tianjin Municipal Education Commission, the Tianjin Key Laboratory of Cerebrovascular and Neurodegenerative Diseases was officially founded on June 6, 2013. The founding director was Professor Wang Jinhuan, former President of Tianjin Huanhu Hospital. Following a leadership transition in August 2025, Professor Wu Jialing, Vice President of Tianjin Huanhu Hospital, took office as the second laboratory director. Concurrently, Professor Ming Dong, Vice President of Tianjin University, serves as Chairs of the Laboratory’s Academic Committee.
Adhering to the operational principles of “openness, mobility, collaboration and competition,” the laboratory targets key scientific challenges rooted in clinical practice. Leveraging the extensive clinical and academic strengths of Tianjin Huanhu Hospital, —which houses a National Regional Medical Center for Neurological Diseases, a National Demonstration Advanced Stroke Center, two National Key Clinical Specialties, and two Tianjin Municipal Key Disciplines—the Laboratory is dedicated tocutting-edge research in cerebrovascular and neurodegenerative diseases. Its research scope covers stroke, neurodegenerative disorders, neuroimmunology and neurorehabilitation, forming an integrated research system that bridges basic research, clinical validation and translational application to drive technological integration and interdisciplinary innovation.
The Laboratory conducts in-depth research across core directions, including the pathogenesis, precision diagnosis and targeted treatment of stroke; basic and clinical studies on neurodegenerative diseases (with a focus on Parkinson’s disease and dementia); and the regulatory mechanisms of neuroimmunology and neurorehabilitation, as well as the development and translational application of innovative neurotechnologies. Furthermore, it has built specialized clinical databases and biobanks for cerebrovascular diseases and dementia, establishing a solid and high-quality platform to support both fundamental and clinical research initiatives.
The laboratory boasts a high-caliber research team, comprising three recipients of the Special Government Allowance from the State Council, one Tianjin Distinguished Contribution Expert, and two first-tier talents of Tianjin’s “131 Innovative Talent Development Program”. The team includes 5 doctoral supervisors and 24 master’s supervisors. To date, the Laboratory has undertaken 14 key research projects funded by the National Key Research and Development Program of China and the National Natural Science Foundation of China. Its original innovative achievements have been awarded three Second Prizes and one Third Prize of the Tianjin Science and Technology Progress Award.
